FORMULATION, DEVELOPMENT, AND CHARACTERISATION OF CILNIDIPINE LOADED SOLID LIPID NANOPARTICLES
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i9.24666Keywords:
Cilnidipine, Solid lipid nanoparticles, Stearic acid, Glyceryl monostearate, Palmitic acid, Tween-20, Tween-80, Tween-40Abstract
Objective: The aim of the present investigation is to develop solid lipid nanoparticles (SLNs) of cilnidipine using hot homogenization followed by ultrasonication technique and to improve the dissolution characteristics of the drug.
Methods: The cilnidipine-loaded SLNs were formulated using stearic acid (SA), glyceryl monostearate (GMS), and palmitic acid (PA) as lipid matrix and tween-20, tween-80, and tween-40 as an emulsifier by hot homogenization and ultrasonication method. The physicochemical characteristics of SLN were analyzed for Fourier transform infrared studies, entrapment efficiency (EE), zeta potential, in vitro drug release, particle size analysis, scanning electron microscopy, and stability.
Results: The SLNs with PA showed a sustained release of drug 82%–88%, respectively, after 10 h. The SLNs of PA using tween-80 as emulsifier resulted with high EE% than SLNs of SA and GMS. The compatibility studies are done by Fourier transformed infrared for formulations which contain PA as lipid matrix and tween-80 as an emulsifier, and it showed no drug excipient incompatibility. The formulation containing PA and tween-80 shown particles of average size 152 nm having polydispersity index of. 217 with 68.7 % EE were produced. The zeta potential of the formulation was found to be – 27 mV and the order of percentage drug release was from PA>GMS>SA, and steric stabilizers retard the drug release more than ionic stabilizers.
Conclusion: SLN formulations showed the best results in EE as well as in in vitro drug release and therefore confirmed that the novel drug delivery system provides an improved strategy for the treatment of hypertension.
Downloads
References
Akter M, Banik S, Hossain MS. In vitro evaluation of oral extended release drug delivery system for metoprolol succinate using kollidon SR.J App Pharma Sci 2012;25:188-92.
Kumar PS, Arivuchelvan A, Jagadeeswaran A, Subramanian N. Formulation, optimization and evaluation of enrofloxacin solid lipid nanoparticles for sustained oral delivery. Asian J Pharm Clin Res 2015;8:231-6.
Christensen HR, Antonsen K, Simonsen K, Lindekaer A, Bonde J, Angelo HR, et al. Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: Half-life shorter than expected? Pharmacol Toxicol 2000;86:178-82.
Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release 2008;128:185-99.
Radtke M, Muller RH. Nanostructured lipid drugcarriers. New Drugs 2001;2:48-52.
Jores K, Mehnert W, Bunjes H, Drechsler M, Mader K. Solid Lipid Nanoparticles (SLN) to Nanospoons. Visions and Reality of Colloidal Lipid Dispersions. Nuremberg, Germany: International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 2008. p. 15-8.
Saupe A, Gordon KV, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryofield emission scanning electron microscopy and raman spectroscopy. Int J Pharm 2006;314:56-62.
Venkateshwarlu V, Manjunath K. Preparation and in vitro release kinetics of clozapine solid lipid nanoparticles. J Controlled Release 2004;95:627-38.
Maruthi G, Smith AA, Manavalan R. Nanoparticles–a review. J Adv Sci Res 2011;2:12-29.
Monk JP, Campoli-Richards DM. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1987;33:346-91.
Mishra R, Mir SR, Amin S. Polymeric nanoparticles for improved bioavailability of clinidipine. Int J Pharm Pharm Sci 2017;9:129-39.
Martinez M, McDermott P, Walker R. Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals. Vet J 2006;172:10-28.
Ekambaram P, Sathali AA. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011;3:216-20.
Saito A, Sawatari K, Fukuda Y, Nagasawa M, Koga H, Tomonaga A, et al. Susceptibility of legionella pneumophila to ofloxacin in vitro and in experimental legionella pneumonia in guinea pigs. Antimicrob Agents Chemother 1985;28:15-20.
Kumar BV, Babu BP, Prasad G. Formulation and evaluation of isradipine buccal tablets. Res J Pharm Tech 2012;5:1-10.
Todd PA, Ofloxacin FD. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991;42:825-76.
Shelat P, Mandowara VK, Gupta DG, Patel S. Formulation of curcuminoid loaded solid lipid nanoparticles in order to improve oral bioavailability. Int J Pharm Pharm Sci 2015;7:278-2.
Priya S, Koland M, Kumara S. Formulation and characterization of ropinirole hydrochloride loaded solid lipid nanoparticles. Int J Pharm Pharm Sci 2015;7:85-9.
Prajapati ST, Maheshwari PD, Chhaganbhai N. Patel formulation and evaluation of orodispersible tablets of clinidipine by spray drying technique. World J of Pharm Pharm Sci 2015;45:1526-39.
Wang F, Gu XJ, Zhang MF, Tai TY. Treatment of typhoid fever with ofloxacin. J Antimicrobial Chemother 1989;23:785-8.
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
Gamal A. Shazly ciprofloxacin controlled solid lipid nanoparticles characterization, in-vitro release and antibacterial activity assessment. Biomed Res Int 2017;2017:1-9.
Gaspar DP, Faria V, Gonçalves LM, Taboada P, Remuñán-López C, Almeida AJ, et al. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. Int J Pharm 2016;497:199-209.
Gentry LO, Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991;35:538-41.
Sadiq AA, Rassol AA. A formulation and evaluation of silibinin loaded solid lipid nanoparticles for peroral use targeting lower part of gastrointestinal tract. Int J Pharm Pharm Sci 2014;1:55-67.
Jensen LB, Magnussson E, Gunnarsson L, Vermehren C, Nielsen HM, Petersson K. Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles. Int J Pharm 2010;390:53-60.
Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul 1999;16:205-13.
Zimmermann E, Müller RH, Mäder K. Influence of different parameters on reconstitution of lyophilized SLN. Int J Pharm 2000;196:211-3.
Havanoor SM. Isradipine loaded solid lipid nanoparticles for better treatment of hypertension – preparation, characterization and in vivo evaluation. International Journal of Biopharmaceutics 2014;5:218-24.
Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K. Improved dissolution of ofloxacin via solid dispersion. Int J Pharm 1997;156:175-80.
Agro AS, Garner ET, Wright JW, de Escobar C, Villeda B, Seidlin M. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998;20:744-59.
Al-Tahami K. Preparation, characterization, and in vitro release of ketoprofen loaded alginate microspheres. Int J Appl Pharm 2014;6:9-12.
Fogari R, Malacco E, Tettamanti F, Gnemmi AE, Milani M. Evening vs morning isradipine sustained release in essential hypertension: A double-blind study with 24 h ambulatory monitoring. Br J Clin Pharmacol 1993;35:51-4.
Laxmi GA, Dachinamoorthy D, Babu YR, Surekha ML, Swamy GK. Development and validation of isradipine in bulk and its pharmaceutical formulation by the RP-HPLC method. Int Res J Pharm 2012;39:1-3.
Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010;17:585-90.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
